Bausch Health Companies Inc. stocks have been trading up by 13.62 percent following upbeat sentiment over improving debt and restructuring prospects.
Click Here for a Millionaire's POV on Trading BHC
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Market Insights For BHC Traders
- Q2 non-GAAP EPS of $1.26 versus $1.01 consensus and revenue of $2.85B versus $2.66B confirmed Bausch Health Companies Inc.’s 13th straight quarter of revenue and adjusted EBITDA growth.
- Strong adjusted operating cash flow and net debt reduction give BHC more room to manage its heavy balance sheet and fund targeted growth.
- 2026 guidance calls for $10.79B–$11.04B in revenue and $4.05B–$4.175B in adjusted EBITDA, both slightly ahead of prior Street expectations.
- Shares jumped roughly 26%–27% after the Q2 beat and raised 2026 outlook, signaling aggressive re-pricing by traders.
- RBC Capital kept a Sector Perform rating with a $9 target, flagging Xifaxan patent litigation, possible Bausch + Lomb monetization, and forex as key swing factors.
Weekly Update Jul 27 – Jul 31, 2026: On Sunday, August 02, 2026 Bausch Health Companies Inc. stock [NYSE: BHC] is trending up by 13.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Bausch Health sits in a transitional but improving position: high gross margin (≈79%) and solid EBITDA margin (≈19%) contrast with still-weak pre‑tax and net margins, burdened by heavy interest expense (coverage only 1.3x) and negative equity from legacy leverage and intangibles. Nonetheless, Q2 EBIT of $744m and free cash flow of $593m on $2.85b revenue underscore strong cash generation, a modest net debt reduction trend, and a distressed 0.25x P/S valuation that materially discounts RemainCo’s earnings power.
Technically, BHC has shifted from a low‑vol, sub‑$5 base into a momentum breakout: the weekly sequence from ~$4.50 to an intraday high above $7 with strong volume confirms a new uptrend and short‑covering. The key actionable level is ~$6.00, where prior resistance should now act as first support; above, $7.00–7.10 is immediate resistance. A constructive strategy is to accumulate near $6.00 with a stop around $5.40, targeting a move back through $7.00.
More Breaking News
- Integer Holdings Surges As Analysts Lift Price Targets
- MPWR Surges As Monolithic Power Systems Hikes Outlook
- JMKE Surges As Jersey Mike’s IPO Demand Overwhelms Supply
- OLN Stock Slides After Q2 Loss Deepens And Price Targets Cut
Fundamentally, upside catalysts dominate: 13 consecutive quarters of YoY revenue and adjusted EBITDA growth (ex‑B+L), guidance above Street on both revenue and EBITDA, and strong operating cash flow all support a rerating versus healthcare and specialty‑pharma peers. Major swing factors remain Xifaxan patent outcomes and pace/structure of Bausch + Lomb monetization to accelerate deleveraging. With the stock near $6.80 after a 25–30% post‑earnings spike, I see a 6–12 month risk‑reward skewed higher, with a $9–10 target and strong support near $5.50.
Quick Financial Overview
Bausch Health Companies Inc. just printed a clean beat: Q2 non-GAAP EPS at $1.26 versus $1.01 consensus and revenue at $2.85B versus $2.66B. That marks 13 straight quarters of year-over-year revenue and adjusted EBITDA growth for BHC’s core business excluding Bausch + Lomb, which tells traders this is not a one-off surprise. With gross margin near 78.9% and EBITDA margin around 19.4%, the company still throws off solid cash from a high-margin portfolio.
The balance sheet is heavy but moving in the right direction. Bausch Health reported strong adjusted operating cash flow of about $670M for the quarter and free cash flow around $593M, alongside a meaningful cut in net debt. Long-term debt is roughly $19.9B against total assets of about $24.8B and negative common equity, so leverage remains a central theme, but an interest coverage ratio near 1.3 is slowly getting some cushion from higher EBITDA and lower net debt.
On the tape, BHC has re-rated fast. Weekly data show the stock moving from the mid-$4s to as high as about $7.01 by 2026/07/31, with a key gap from a $4.88 close to a $6.03 open the next day — a textbook reaction to a major earnings surprise and guidance hike. Intraday, a 5-minute candle opening near $6.00 and closing just under $6.90 after touching roughly $6.92 underscores strong demand absorbing profit-taking. For traders, that kind of closing strength after a gap-up is a classic momentum continuation signal, especially when backed by improved guidance calling for 2026 revenue of $10.79B–$11.04B and adjusted EBITDA of $4.05B–$4.175B.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.